Evidence map›Paper›PMID 40006676›Full record

ArticleVaccines2025

Efficacy of LaAg Vaccine Associated with Saponin Against

Mirian França de Mello, Patrícia de Almeida Machado, Pollyanna Stephanie Gomes, Gabriel Oliveira-Silva, Monique Pacheco Duarte Carneiro, Tadeu Diniz Ramos, Juliana Elena Silveira Pratti, Raquel Peralva, Luan Firmino-Cruz, Alda Maria Da-Cruz and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mirian França de MelloLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Patrícia de Almeida MachadoLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Pollyanna Stephanie GomesLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0002-8283-3369
Gabriel Oliveira-SilvaLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Monique Pacheco Duarte CarneiroLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Tadeu Diniz RamosLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Juliana Elena Silveira PrattiLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Raquel PeralvaLaboratório Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil.
Luan Firmino-CruzLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0001-8971-8163
Alda Maria Da-CruzLaboratório Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil.ORCID 0000-0001-7455-2447
Luciana CovreLaboratório de Imunobiologia, Núcleo de Doenças Infecciosas/Núcleo de Biotecnologia, Universidade Federal do Espírito Santo, Vitória 29047-105, ES, Brazil.ORCID 0000-0001-5877-0137
Daniel Claúdio Oliveira GomesLaboratório de Imunobiologia, Núcleo de Doenças Infecciosas/Núcleo de Biotecnologia, Universidade Federal do Espírito Santo, Vitória 29047-105, ES, Brazil.
Bartira Rossi-BergmannLaboratório de Imunofarmacologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Eduardo Fonseca PintoLaboratório Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil.ORCID 0000-0001-7242-4206
Alessandra Marcia da Fonseca-MartinsLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Herbert Leonel de Matos GuedesLaboratório de Imunobiotecnologia, Instituto de Microbiologia Paulo Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.

Funding

Capes NAFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro NANational Council for Scientific and Technological Development NA
6 · The paper itself

Abstract

BACKGROUND/

objectivesThe total lysate of

methodsBALB/c mice were immunized with LaAg in combination with various adjuvants. The delayed-type hypersensitivity (DTH) test was assessed by measuring the infected paw and was used to evaluate the immunogenicity and to determine the most effective adjuvant. The immune response was analyzed through flow cytometry, focusing on cytokine production, immune cell recruitment and lesion size, alongside the control of parasite load at the infection site. The expression levels of iNOS and TGF-β were quantified using RT-qPCR, while IgG1, IgG2a and IgE antibody levels were determined via ELISA.

resultsAmong the adjuvants tested, only saponin (SAP) elicited a significant DTH response following LaAg challenge. SAP enhanced the immunogenicity of LaAg, as evidenced by increased IFN-γ-producing CD4

conclusionsThe LaAg + SAP combination conferred partial protection, as demonstrated by a reduction in lesion size and the partial control of parasite load. In conclusion, the addition of SAP as an adjuvant to LaAg effectively modulates the immune response, enhancing the vaccine's protective efficacy. These findings provide valuable insights into the development of improved vaccines against

Indexed as

Leishmaniasaponinvaccine

Identifiers

PMID40006676
PMCPMC11861163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.